# Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy

> **NCT00509093** · PHASE2 · COMPLETED · sponsor: **Case Comprehensive Cancer Center** · enrollment: 32 (actual)

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** imatinib mesylate
- **GENETIC:** gene expression analysis
- **GENETIC:** mutation analysis
- **GENETIC:** polymerase chain reaction
- **OTHER:** flow cytometry
- **PROCEDURE:** biopsy

## Key facts

- **NCT ID:** NCT00509093
- **Lead sponsor:** Case Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-10
- **Primary completion:** 2014-05-09
- **Final completion:** 2015-04-09
- **Target enrollment:** 32 (ACTUAL)
- **Last updated:** 2020-03-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00509093

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00509093, "Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT00509093. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*